Stryker Corporation operates as a medical technology company.
$325.78-2.78%
报价 2026-11-06
市值
$124.02B
EV
$138.13B
PE (TTM)
39.2x
预期 PE (FY2026)
22.0x
52 周区间距高点 -15.9%
$269.75$387.46
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
does not hit growth, cheap, or GARP pool
爆发潜力
2026-11-07未命中✗ 收入线✗ EPS 线
| 财年 | 收入倍数 | EPS | PE |
|---|---|---|---|
| FY+22027-12 | 1.1x | 14.28 → 16.33（1.1x） | 20.0 |
| FY+32028-12 | 1.2x | 14.28 → 18.09（1.3x） | 18.0 |
毛利率 64% · TTM 收入 $26300M · 基数 EPS 14.28（调整后）
电话会信号
辅助标签Q3 20262026-10-29
扩产AI 词频高下调/撤回指引供不应求
指引 下调
信心 3
分析师 2
“We expect to deliver growth at the high end of our markets in 2027.”
原文引用（3）
- 扩产：we're actually building extra capacity, especially in beds
- 下调/撤回指引：we are revising our full year guidance to reflect softer hip and knee procedure trends
- 供不应求：we're not draining our backlog
蓝色标签在暴涨研究中略有区分度；悬停查看口径。
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| SYKStryker Corporation | $124.02B | -2.8% | +8.8% | 63.5% | 39.2x | 24.7x | 28.9x | |
| AMGNAmgen Inc. | $248.92B | +0.0% | +4.0% | 70.5% | 24.4x | 12.5x | 30.7x | |
| GILDGilead Sciences, Inc. | $207B | -0.4% | +4.1% | 81.1% | 20.0x | 14.5x | 21.9x | |
| PFEPfizer Inc. | $167.51B | -0.2% | +1.4% | 72.8% | 37.3x | 17.7x | 14.7x | |
| DHRDanaher Corporation | $161.86B | +1.7% | +3.8% | 60.9% | 37.2x | 21.3x | 30.8x | |
| VRTXVertex Pharmaceuticals Incorporated | $138.67B | +0.8% | +8.8% | 86.3% | 29.0x | 23.5x | 43.4x | |
| MDTMedtronic plc | $130.22B | -2.9% | +8.0% | 62% | 24.2x | 14.8x | – | |
| MCKMcKesson Corporation | $123.68B | -1.0% | +6.6% | 3.6% | 24.9x | 17.6x | 12.2x | |
| SNYSanofi | $113.26B | +0.3% | – | 71.7% | 8.9x | 9.7x | – | |
| 同行中位数 | – | – | +4.1% | 71.1% | 24.7x | 16.2x | 26.3x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。
研究材料
Filing 摘要
电话会纪要摘要
暂无纪要摘要。